Sugi Predict

Sugi Predict / Compounds / SCHEMBL4049267

SCHEMBL4049267

SCHEMBL4049267

COc1cccc(-n2nc(C)cc2NC(=O)Nc2cccc(Cl)c2)c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.78
▸ MEN1 O00255 2/20 0.63
▸ KMT2A Q03164 2/20 0.63
▸ KCNJ6 P48051 6/20 0.61
▸ KCNJ3 P48549 6/20 0.61
▸ KCNJ5 P48544 5/20 0.61
▸ TSHR P16473 1/20 0.61
▸ MAPK14 Q16539 2/20 0.60
▸ MAPK13 O15264 1/20 0.60
▸ MAPK12 P53778 1/20 0.60
▸ MAPK11 Q15759 1/20 0.60
▸ NPSR1 Q6W5P4 2/20 0.59
▸ HTT P42858 3/20 0.57
▸ LMNA P02545 2/20 0.57
▸ GAA P10253 2/20 0.57
▸ ALDH1A1 P00352 1/20 0.57
▸ HPGD P15428 1/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.57
▸ NTRK1 P04629 2/20 0.56
▸ ALPG P10696 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4049965 0.92 KCNJ6 (0.67) MAPTMEN1KMT2AKCNJ6KCNJ3
SCHEMBL13234481 0.88 MAPT (1.00) MAPTMEN1KMT2AKCNJ6KCNJ3
SCHEMBL4054036 0.87 KCNJ6 (0.61) MAPTMEN1KMT2AKCNJ6KCNJ3
SCHEMBL2081640 0.87 MAPK14 (0.81) MAPTMAPK14MAPK13MAPK12MAPK11
SCHEMBL13576976 0.86 PTPN1 (0.64) MAPTKCNJ6KCNJ3KCNJ5MAPK14
SCHEMBL4302251 0.85 KCNJ6 (0.62) MAPTMEN1KMT2AKCNJ6KCNJ3
SCHEMBL4051391 0.82 MAPK14 (0.77) MAPTMAPK14MAPK11NPSR1NTRK1
SCHEMBL25002342 0.80 MAPT (0.73) MAPTMEN1KMT2ATSHRHTT
SCHEMBL2083861 0.79 MAPK14 (0.79) MAPTMAPK14MAPK13MAPK12MAPK11
SCHEMBL2080417 0.78 MAPK14 (0.79) MAPK14MAPK13MAPK12MAPK11BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC 2009-12-17 — — US disclosed
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC 2009-12-17 — — US disclosed
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC 2009-12-17 — — US disclosed
EP-1836173-A4 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS LLC (US) 2009-07-08 — — EP disclosed
EP-1836173-A2 ANTI-INFLAMMATORY MEDICAMENTS Deciphera Pharmaceuticals, LLC (US) 2007-09-26 — — EP disclosed
US-20070191336-A1 p38 kinase inhibitors DECIPHERA PHARMACEUTICALS, LLC 2007-08-16 — — US disclosed
US-20070191336-A1 p38 kinase inhibitors DECIPHERA PHARMACEUTICALS, LLC 2007-08-16 — — US disclosed
US-20070191336-A1 p38 kinase inhibitors DECIPHERA PHARMACEUTICALS, LLC 2007-08-16 — — US disclosed
WO-2006081034-A2 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2006-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS ABL2, ABL1, PTK2 MAPT 2609/4885MEN1 4734/4885KMT2A 2977/4885
US-20070191336-A1 p38 kinase inhibitors MAPK1, MAP3K8, MAP3K1 MAPT 1430/4885MEN1 4811/4885KMT2A 3389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.